Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005212 | Clinical Therapeutics | 2005 | 12 Pages |
Abstract
Among the available CBZ formulations, Carbatrol was associated with a lower incidence of common CNS adverse events. ER-CBZ formulations were also associated with reduced likelihood of therapy discontinuation or switching CBZ medications, relative to patients taking generic IR-CBZ, in this retrospective data analysis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
PharmD Garnett, MS Gilbert, RPh, MBA O'Connor,